65,437 trials
Familial Amyloid Polyneuropathy
Primary: Percentage of Participants With Response to Treatment as Measured by Neuropathy Impairment Score - Lower Limb (NIS-LL) at Month 18 — 45.3; 29.5 percentage of participants
Schizophrenia
Primary: Cognitive Function- Digit Span Total — 13.3; 14.1 Items correct
Ankylosing Spondylitis · Axial Spondyloarthritis
Primary: Number of Participants Achieving the Assessment in Ankylosing Spondylitis (ASAS) Partial Remission Criteria at Week 28 — 65; 18; 40; 33 Participants
Familial Amyloid Polyneuropathy · ATTR-PN
Primary: Percentage of Participants With Response to Treatment as Measured by Neuropathy Impairment Score - Lower Limb (NIS-LL) at Month 6 — 62.2; 68.8 percentage of participants
Prostate Cancer
Primary: The Number of Men With Advanced Prostate Cancer Treated With Sunitinib Who Have a Prostate Specific Antigen (PSA) Response — 2 participants
Glioblastoma Multiforme
Primary: Progression-free Survival — 6 Months
Parkinson Disease
Primary: Number of Participants With the Indicated Types of Adverse Events (AEs) and Serious Adverse Events (SAEs) During the On-Treatment Phase (Comprised of the Open-label…
Rheumatoid Arthritis
Primary: ACR 20 Response Rate at Visit 4 — 108; 34 participants — p=0.0010
Type 2 Diabetes
Primary: Number of Participants Who Experienced One or More Adverse Events During the Study — 2; 6; 4; 9 participants
Breast Cancer
Primary: Objective Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 20 percentage of participants
Rheumatoid Arthritis
Primary: Percent Change From Baseline (Week 6) in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Week 12 — -35.34; 5.80 percent change
Stage IV Melanoma
Primary: Median Time of Progression-free Survival — 2.20; 1.95 Months
Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma · Recurrent Primary Peritoneal Carcinoma
Primary: Complete and Partial Response Rate Using the Response Evaluation Criteria in Solid Tumors (RECIST) Criteria — 2; 11; 1; 8 participants
Environmental Exposure
Primary: Tear Evaporation Rate — 39.0; 44.8; 30.6; 26.7 Watt/meter^2
Hypertension · Ischemic Heart Disease · Congestive Heart Failure
Primary: New Onset or Recurrence of Stroke — 25; 46 event number — p=<0.05